Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,089 JPY | -0.02% | +0.49% | +0.86% |
04-26 | EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug | MT |
04-26 | Hutchmed notes CHMP's positive opinion for fruiquintinib approval | AN |
Sales 2024 * | 4,099B 25.88B 2,072B | Sales 2025 * | 4,028B 25.43B 2,037B | Capitalization | 6,415B 40.5B 3,243B |
---|---|---|---|---|---|
Net income 2024 * | 134B 846M 67.75B | Net income 2025 * | 234B 1.48B 118B | EV / Sales 2024 * | 2.48 x |
Net Debt 2024 * | 3,771B 23.8B 1,906B | Net Debt 2025 * | 3,438B 21.7B 1,738B | EV / Sales 2025 * | 2.45 x |
P/E ratio 2024 * |
46.4
x | P/E ratio 2025 * |
27.6
x | Employees | 49,095 |
Yield 2024 * |
4.6% | Yield 2025 * |
4.64% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 day | -0.02% | ||
1 week | +0.49% | ||
Current month | -2.27% | ||
1 month | -6.69% | ||
3 months | -5.13% | ||
6 months | -5.94% | ||
Current year | +0.86% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 31/03/14 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 31/01/22 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 31/12/11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 31/05/16 | |
Ian Clark
BRD | Director/Board Member | 62 | 31/12/18 |
Steven Gillis
BRD | Director/Board Member | 71 | 31/12/18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
24.44% | 15 M€ | +7.34% | ||
5.00% | 284 M€ | +23.00% | ||
3.80% | 1,552 M€ | +18.10% | ||
3.43% | 251 M€ | +13.17% | ||
3.26% | 57 M€ | +19.27% |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 4,089 | -0.02% | 3,185,300 |
25/04/24 | 4,090 | -1.09% | 2,910,500 |
24/04/24 | 4,135 | +0.32% | 3,228,000 |
23/04/24 | 4,122 | -0.15% | 2,747,100 |
22/04/24 | 4,128 | +1.45% | 3,521,200 |
Delayed Quote Japan Exchange, April 26, 2024 at 07:00 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.86% | 40.76B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 4502 Stock